Hypercortisolism in obesity-associated hypertension

Current Hypertension Reports

Volumn 16, Issue 7, 2014, Pages

  Varughese, Amy G ^a   Nimkevych, Oksana ^a   Uwaifo, Gabriel I ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiposity; Aldosterone; Cortisol; Cortisol associated hypertension; Cortisone; Dexamethasone; Dysmetabolic syndrome; Elevated blood pressure; Exogenous Cushing's syndrome; Glucocorticoid excess; Glucocorticoid induced hypertension; Glucocorticoids; Hydrocortisone; Hypercortisolism; Insulin resistance; Mineralocorticoid activation; Obesity hypertension; Pseudo Cushing's syndrome; Subclinical Cushing's syndrome; Visceral fat excess

Indexed keywords

CELL ADHESION MOLECULE; CORTICOTROPIN; DEXAMETHASONE; ENDOTHELIN; EPITHELIAL SODIUM CHANNEL; GLUCOCORTICOID RECEPTOR; HOMOCYSTEINE; HYDROCORTISONE; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; OSTEOPROTEGERIN; VASCULOTROPIN; ANTIHYPERTENSIVE AGENT; GLUCOCORTICOID;

ABDOMINAL OBESITY; ADIPOSE TISSUE; APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL REACTIVITY; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CUSHING DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; HEART OUTPUT; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERCORTISOLISM; HYPERTENSION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; NONHUMAN; OBESITY; OBESITY HYPERTENSION; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN SUBSTRATE; RESISTANT HYPERTENSION; ANIMAL; COMPLICATION; CUSHING SYNDROME; METABOLISM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CUSHING SYNDROME; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; HYPERTENSION; OBESITY;

EID: 84902329631     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0443-y     Document Type: Article

References (60)

1. Dwyer-Lindgren L, Freedman G, Engell RE, Fleming TD, Lim SS, Murray CJ, et al. Prevalence of physical activity and obesity in US counties, 2001-2011: a road map for action. Popul Health Metrics. 2013;11(1):7. doi:10.1186/1478-7954- 11-7.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA: J Am Med Assoc. 2010;303(3):235 - 41. doi:10.1001/jama. 2009.2014.
3. Ford ES, Mokdad AH. Epidemiology of obesity in the Western Hemisphere. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S1-8. doi:10.1210/jc.2008-1356.
4. Maynard LM, SerdulaMK, Galuska DA, Gillespie C,Mokdad AH. Secular trends in desired weight of adults. Int J Obes. 2006;30(9): 1375-81. doi:10.1038/sj.ijo.0803297. (Pubitemid 44306520)
5. .• Uwaifo GI. Obesity-associated hypertension. In: Koch CA, Chrousos GP, editors. Endocrine hypertension; Underlying mechansims and therapy. New York: Humana Press; 2013. p. 251 - 88. A comprehensive discussion of the entity of obesityassociated hypertension, including its recognition, underlying pathophysiology, contributory factors and clinical associations, as well as an exhaustive discussion of the therapeutic options and how they fare in this condition as compared to typical essential hypertension.
6. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol/Eur Fed Endocr Soc. 2007;157(5):545 -59. doi:10. 1530/EJE-07-0455.
7. Kurukulasuriya LR, Stas S, Lastra G, Manrique C, Sowers JR. Hypertension in obesity. Med Clin N Am. 2011;95(5):903-17. doi:10.1016/j.mcna.2011.06.004.
8. Landsberg L. Obesity related hypertension as a metabolic disorder. In: Oparil S, Weber MA, editors. Hypertension; A companion to Brenner and Rector 's the Kidney. Philadelphia: WB Saunders Company; 2000. p. 118-24.
9. Reisin E, Hutchison HG. Obesity-Hypertension; Effetcs on cardiovascular and renal systems; The therapeutic approach. In: Oparil S, Weber MA, editors. Hypertension; acompanion to Brenner and Rector 's the kidney. Philadelphia: WB Saunders Company; 2000. p. 206-11.
10. StevensVJ,Obarzanek E, CookNR, Lee IM,Appel LJ, SmithWest D, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134(1):1-11. (Pubitemid 32037337)
11. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682-6. doi:10.1016/S0140- 6736(01)06710-1.
12. Kil DY, Swanson KS. Endocrinology of obesity. Vet Clin N Am Small Anim Pract. 2010;40(2):205-19. doi:10.1016/j.cvsm.2009. 10.004.
13. .• Abraham SB, Rubino D, Sinaii N, Ramsey S, Nieman LK. Cortisol, obesity, and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity. 2013;21(1):E105 -17. doi:10.1002/oby. 20083. An important clinical study that details the problems with interpreting findings from HPA-axis investigation in obese subjects without overt Cushing's syndrome and reviews the conflicting literature on the findings in this regard. Also highlights the important distinction between findings regarding systemic cortisol dynamics as opposed to local tissue dynamics.
14. Baid S, Nieman LK. Glucocorticoid excess and hypertension. Curr Hypertens Rep. 2004;6(6):493-9. (Pubitemid 39600106)
15. .• Morton NM. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol. 2010;316(2):154-64. doi:10.1016/j.mce.2009.09.024. A comprehensive discussion of the role and place of 11 beta HSD-type 1 in the normal physiology of cortisol metabolism, its role and place in obesity, hypercortisolemic states and a detailed discussion of relevant animal models, relevnace to clinical therapeutics and potential future directions in innovation and research.
16. • De Leo M, Cozzolino A, Colao A, Pivonello R. Subclinical Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. 2012;26(4):497-505. doi:10.1016/j.beem.2012.02.001. A topical discussion of the controversial topic of subclinical Cushing's syndrome including its prevalence, clinical presentation, diagnostic evaluation protocols with the controversies therein, as well as discussion of its association with increased cardiovascular risk, associated comorbidites including hypertension and the current available management strategies.
17. Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in Cushing 's syndrome. Best Pract Res Clin Endocrinol Metab. 2006;20(3):467-82. doi:10.1016/j.beem.2006.07.006.
18. .• Sharma ST, Nieman LK. Cushing's syndrome: all variants, detection, and treatment. Endocrinology and metabolism clinics of North America. 2011;40(2):379-91, viii-ix. doi:10.1016/j.ecl.2011.01.006. A thorough review of the various etiolic considerations in the differential diagnosis of Cushing 's syndrome and other hypercortisolemic states, their association with hypertension, and a discussion of the available therapeutic options.
19. Whitworth JA, BrownMA, Kelly JJ,Williamson PM. Mechanisms of cortisol-induced hypertension in humans. Steroids. 1995;60(1):76-80.
20. Kelly JJ, Martin A, Whitworth JA. Role of erythropoietin in cortisol-induced hypertension. J Hum Hypertens. 2000;14(3):195-8. (Pubitemid 30153633)
21. Mantero F, Boscaro M. Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol. 1992;43(5):409-13.
22. .• Ong SL, Whitworth JA. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinology and metabolism clinics of North America. 2011;40(2):393-407, ix. doi:10.1016/j.ecl.2011.01.010. A comprehensive discussion of the basic and animal model-based data that detail the role of glucocorticoids in influencing vascular tone, compliance and endothelial reactivity, as well as the relevance of this to the development of glucocorticoid-induced hypertension in both animal models and human patients.
23. Chandran DS, Jaryal AK, Jyotsna VP, Deepak KK. Impaired endothelium mediated vascular reactivity in endogenous Cushing's syndrome. Endocr J. 2011;58(9):789-99.
24. Whitworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag. 2005;1(4):291-9.
25. Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol. 2004;2(1):1-12. (Pubitemid 38855010)
26. Yiu KH, Marsan NA, Delgado V, Biermasz NR, Holman ER, Smit JW, et al. Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. Eur J Endocrinol/Eur Fed Endocr Soc. 2012;166(1):27 - 34. doi:10.1530/EJE-11-0601.
27. Hattori T, Murase T, Sugiura Y, Nagasawa K, Takahashi K, Ohtake M, et al. Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury. Hypertens Res: Off J Jpn Soc Hypertens. 2014;37(2):125-33. doi:10.1038/hr. 2013.124.
28. Ermetici F,Malavazos AE, Corbetta S, Eller-Vainicher C, Cannavo S, Corsi MM, et al. Soluble adhesion molecules levels in patients with Cushing's syndrome before and after cure. J Endocrinol Investig. 2008;31(5):389-92. (Pubitemid 352003232)
29. Kristo C, Ueland T, Godang K, Aukrust P, Bollerslev J. Biochemical markers for cardiovascular risk following treatment in endogenous Cushing 's syndrome. J Endocrinol Investig. 2008;31(5):400-5. (Pubitemid 352003234)
30. Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, et al. Hyperhomocysteinemia in patients with Cushing's syndrome. J Clin Endocrinol Metabol. 2004;89(8):3745-51. doi:10.1210/jc. 2004-0079.
31. Oki K, Gomez-Sanchez EP, Gomez-Sanchez CE. Role of mineralocorticoid action in the brain in salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2012;39(1):90-5. doi:10.1111/j.1440- 1681.2011.05538.x.
32. DuclosM, Corcuff JB, Etcheverry N, RashediM, Tabarin A, Roger P. Abdominal obesity increases overnight cortisol excretion. J Endocrinol Investig. 1999;22(6):465-71. (Pubitemid 29355564)
33. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev. 1998;19(5):647-72. doi:10.1210/ edrv.19.5.0346.
34. Salehi M, Ferenczi A, Zumoff B. Obesity and cortisol status. Horm Metab Res Horm Stoffwechselforschung Horm Metabol. 2005;37(4):193-7. doi:10.1055/s-2005-861374. (Pubitemid 40756337)
35. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94(8):2692 - 701. doi:10.1210/jc.2009- 0370.
36. Ahluwalia IB, Mack KA, Murphy W, Mokdad AH, Bales VS. State-specific prevalence of selected chronic disease-related characteristics-Behavioral Risk Factor Surveillance System, 2001. Morbid Mortal Wkly Rep Surveill Summ. 2003;52(8):1-80.
37. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet. 1997;349(9060):1210-3. doi:10.1016/S0140-6736(96)11222-8. (Pubitemid 27190044)
38. Pasquali R. The hypothalamic-pituitary-adrenal axis and sex hormones in chronic stress and obesity: pathophysiological and clinical aspects. Ann N YAcad Sci. 2012;1264:20-35. doi:10.1111/j.1749-6632.2012.06569.x.
39. Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R, et al. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab. 1993;77(2):341 - 6. doi:10.1210/jcem.77.2.8393881.
40. Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. Cardiol Clin. 2010;28(4):639-54. doi:10.1016/j.ccl.2010.07.002.
41. Aldhahi W, Mun E, Goldfine AB. Portal and peripheral cortisol levels in obese humans. Diabetologia. 2004;47(5):833-6. doi:10.1007/s00125-004-1389-4. (Pubitemid 38756995)
42. Stimson RH, Andersson J, Andrew R, Redhead DN, Karpe F, Hayes PC, et al. Cortisol release from adipose tissue by 11 betahydroxysteroid dehydrogenase type 1 in humans. Diabetes. 2009;58(1):46-53. doi:10.2337/db08-0969.
43. Alfonso B, Araki T, Zumoff B. Is there visceral adipose tissue (VAT) intracellular hypercortisolism in human obesity? Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2013;45(5):329-31. doi:10.1055/s-0033-1337986.
44. Prodam F, Ricotti R, Agarla V, Parlamento S, Genoni G, Balossini C, et al. High-end normal adrenocorticotropic hormone and cortisol levels are associated with specific cardiovascular risk factors in pediatric obesity: a cross-sectional study. BMC Med. 2013;11:44. doi:10.1186/1741-7015-11-44.
45. Bravo EL. The adrenal cortex. In: Oparil S, Weber MA, editors. Hypertension; a companion to Brenner and Rector 's the kidney. Philadelphia: WB Saunders Company; 2000. p. 682-5.
46. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-40. doi:10.1210/jc.2008-0125. (Pubitemid 351656485)
47. .• Kantorovich V, Koch CA, Chrousos GP. Hypertension in patients with Cushing's syndrome. In: Koch CA, Chrousos GP, editors. Endocrine hypertension; Underlying mechansims and therapy. New York: Humana press; 2013. p. 51-68. A comprehensive review of the etiopathogenesis of hypertension in Cushing's syndrome, the treatment options, and its relevance to hypertension in obesity in general.
48. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242(4878):583-5. (Pubitemid 18263202)
49. Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev. 2005;10(1):15-22. doi:10.1007/s10741-005-2344-2. (Pubitemid 40895312)
50. Pearce D, Verrey F, Chen SY, Mastroberardino L,Meijer OC,Wang J, et al. Role of SGK in mineralocorticoid-regulated sodium transport. Kidney Int. 2000;57(4):1283-9. doi:10.1046/j.1523-1755.2000.00963.x. (Pubitemid 30207879)
51. Staub O, Abriel H, Plant P, Ishikawa T, Kanelis V, Saleki R, et al. Regulation of the epithelial Na+ channel by Nedd4 and ubiquitination. Kidney Int. 2000;57(3):809-15. doi:10.1046/j.1523-1755.2000.00919.x. (Pubitemid 30434770)
52. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet. 1996;347(8994):88-91. (Pubitemid 26017854)
53. White PC. 11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Am J Med Sci. 2001;322(6):308-15. (Pubitemid 33139184)
54. Whorwood CB, Stewart PM. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess. J Hypertens Suppl: Off J Int Soc Hypertens. 1996;14(5):S19-24. (Pubitemid 27051074)
55. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens. 2004;13(4):451-8. (Pubitemid 38901625)
56. Stewart PM, Edwards CR. The cortisol-cortisone shuttle and hypertension. J Steroid Biochem Mol Biol. 1991;40(4-6):501-9.
57. Strohmayer EA, Krakoff LR. Glucocorticoids and cardiovascular risk factors. Endocrinology and metabolism clinics of North America. 2011;40(2):409-17, ix. doi:10.1016/j.ecl.2011.01.011.
58. Minami I, Tateno T, Yoshimoto T, Doi M, Izumiyama H, Akashi T, et al. Subclinical Cushings disease with amelioration of metabolic comorbidities after removal of pituitary tumor. Intern Med. 2006;45(21):1231-5. (Pubitemid 44848859)
59. Fallo F, Paoletta A, Tona F, Boscaro M, Sonino N. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. J Intern Med. 1993;234(6):595-8. (Pubitemid 24010362)
60. Fallo F, Sonino N, Barzon L, Pistorello M, Pagotto U, Paoletta A, et al. Effect of surgical treatment on hypertension in Cushing's syndrome. Am J Hypertens. 1996;9(1):77-80. (Pubitemid 26060112)